High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not

Hormone and Metabolic Research

Volumn 40, Issue 5, 2008, Pages 311-314

  Prieto, L M ^a,b   Brown, J W ^a,b   Perez Stable, C ^a,b   Fishman, L M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenal cancer; Apoptosis; DPN; Estrogen; PPT

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 2,3 BIS(4 HYDROXYPHENYL)PROPIONITRILE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HORMONE RECEPTOR STIMULATING AGENT;

ADRENAL CORTEX CARCINOMA; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADRENAL GLAND NEOPLASMS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS; FLOW CYTOMETRY; HUMANS; NITRILES; PHENOLS; PYRAZOLES; RECEPTORS, ESTROGEN;

EID: 45549099394     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1073141     Document Type: Article

References (26)

1. Reincke M. Mutations in adrenocortical tumors. Horm Metab Res 1998; 30: 447-455
2. Bertherat J, Gimenez-Roqueplo AP. New insights in the genetics of adrenocortical tumors, pheochromocytomas and paragangliomas. Horm Metab Res 2005; 37: 384-390
3. Sandrini F, Villain DP, Tucci S, Moreira AC, Castro M de, Elias LL. Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. Horm Metab Res 2005; 37: 231-235
4. Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann KW, Mann K, Petersenn S. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005; 37: 722-728
5. Almeida MQ, Latronico AC. The molecular pathogenesis of childhood adrenocortical tumors. The molecular pathogenesis of childhood adrenocortical tumors. Horm Metab Res 2007; 39: 461-466
6. Kanczkowski W, Morawietz H, Ziegler CG, Funk RH, Schmitz G, Zacharowski K, Mohn CE, Ehrhart-Bornstein M, Bornstein SR. Pam3CSK4 and LTA-TLRs ligands associated with micodomains induce IL8 production in human adrenocortical cancer cells. Horm Metab Res 2007; 39: 457-460
7. Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD/Carney complex, and other bilateral hyperplasias: the NIH studies. Horm Metab Res 2007; 39: 467-473
8. La Rocca RV, Stein CA, Danesi R, Jamis-Dow CA, Weiss GH, Myers CE. Suramin in adrenal cancer Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990; 71: 497-504
9. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer 2007; 14: 13-28
10. Schteingart DE, Doherty GM, Ganger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 2005; 12: 667-680
11. Brown JW, Prieto LM, Perez-Stable C, Montoya M, Cappell S, Fishman LM. Estrogen and progesterone lower cyclin B1 and D1 expression, block cell cycle in G2/M, and trigger apoptosis in human adrenal carcinoma cultures. Horm Met Res 2008; 40: 306-310
12. Lobanova YS, Scherbakov AM, Shatskaya VA, Krasil'nkov MA. Mechanism of estrogen-induced apoptosis in breast cancer cells: Role of the NF-kappaB signaling pathway. Biochemistry (Mosc) 2007; 72: 320-327
13. Cabeza M, Bratoeff E, Heuze I, Guzman A, Gomez G, Berrios H, Rosales AM. Antiandrogenic and apoptotic effects of RU-486 on animal prostate. J Steroid Biochem Mol Biol 2007; 104: 321-325
14. Seeger H, Huober J, Wallwiener D, Mueck AO. Inhibition of human breast cancer cell proliferation with estradiol metabolites is as effective as with tamoxifen. Horm Metab Res 2004; 36: 277-280
15. Seeger H, Rakov V, Mueck AO. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. Horm Metab Res 2005; 37: 468-473
16. Bland LB, Garzotto M, Loughery TG De, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM. Phase II study of transdermal estradiol in androgen-independent prostate cancer. Cancer 2005; 103: 717-723
17. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287-295
18. Blagosklonny MV, Neckers LM. Cytostatic and cytotoxic activity of sex steroids against human leukemia cell lines. Cancer Lett 1994; 76: 81-86
19. 1,2) activity in SW-13 human adrenal carcinoma cells. Horm Metab Res 2001; 33: 127-130
20. Montoya M, Brown JW, Fishman LM. Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. Horm Metab Res 2008; 40: 302-305
21. Leibovitz A, MacCombs 3rd WW, Johnston D, MacCoy CE, Stinson JC. New human cancer cell culture lines. I. SW-13, small-cell carcinoma of the adrenal cortex. J Natl Cancer Inst 1973; 51: 691-697
22. Brown JW, Kesler CT, Neary JT, Fishman LM. Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK1,2) activity in SW-13 human adrenal carcinoma cells. Toxicon 2001; 39: 1835-1839
23. Krishan A. Rapid DNA content analysis by the propidium iodide-hypotonic citrate method. Methods Cell Biol 1990; 33: 121-125
24. Ahola TM, Alkio N, Manninen T, Ylikomi T. Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology 2002; 143: 4620-4626
25. Aizu-Yokota E, Ichinoseki K, Sato Y. Microtubule disruption induced by estradiol in estrogen receptor-positive and -negative human breast cancer cell lines. Carcinogenesis 1994; 15(9): 1875-1879
26. Montanaro D, Maggiolini M, Recchia AG, Sirianni R, Aquila S, Barzon L, Fallo F, Ando S, Pezzi V. Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation. J Mol Endocrinol 2005; 35: 245-256